FWBI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FWBI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-06), First Wave BioPharma's share price is $2.60. First Wave BioPharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-213.12. Hence, First Wave BioPharma's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for First Wave BioPharma's Price-to-Free-Cash-Flow or its related term are showing as below:
First Wave BioPharma's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-2.20. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-213.12.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 84.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 70.90% per year.
During the past 10 years, First Wave BioPharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 84.90% per year. The lowest was 17.30% per year. And the median was 46.85% per year.
The historical data trend for First Wave BioPharma's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Wave BioPharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
First Wave BioPharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, First Wave BioPharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, First Wave BioPharma's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where First Wave BioPharma's Price-to-Free-Cash-Flow falls into.
First Wave BioPharma's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 2.60 | / | -213.118 | |
= | N/A |
First Wave BioPharma's Share Price of today is $2.60.
First Wave BioPharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-213.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
First Wave BioPharma (NAS:FWBI) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of First Wave BioPharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
James Sapirstein | director, officer: President and CEO | 1517 SAN JACINTO, HOUSTON TX 77002 |
Sarah Romano | officer: Chief Financial Officer | 271 WAVERLY OAKS ROAD, WALTHAM MA 02452 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
David Andrew Hoffman | director | 777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431 |
Edward Borkowski | director | 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317 |
Mary Theresa Coelho | director | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
Alastair Riddell | director | C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226 |
Vern Lee Schramm | director | 1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461 |
Gregory Oakes | director | 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226 |
James Pennington | officer: CHIEF MEDICAL OFFICER | 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545 |
Daniel H Schneiderman | officer: CHIEF FINANCIAL OFFICER | 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226 |
Ross Edmund Burke Jr. | 10 percent owner | C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196 |
Johan M. Spoor | director, officer: President and CEO | 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116 |
Maged Shenouda | director | 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011 |
Pelican Partners Llc | 10 percent owner | PO BOX 2422, WESTPORT CT 06880 |
From GuruFocus
By sperokesalga sperokesalga • 02-28-2023
By Stock market mentor Stock market mentor • 01-25-2023
By Marketwired • 07-05-2023
By Marketwired • 09-05-2023
By Stock market mentor Stock market mentor • 01-30-2023
By Stock market mentor Stock market mentor • 01-31-2023
By Marketwired • 09-15-2023
By sperokesalga sperokesalga • 05-15-2023
By Marketwired • 10-03-2023
By Marketwired • 09-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.